Form 10-Q aTYR PHARMA INC For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
aTyr Pharma (LIFE) Trims Q3 Loss
November 11, 2015 7:38 AM ESTaTyr Pharma (NASDAQ: LIFE) reported Q3 EPS of ($0.48), versus ($8.02) reported last year.
For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.
... MoreaTyr Pharma (LIFE) Selects iMod.Fc Molecule as IND Candidate
November 11, 2015 7:37 AM ESTaTyr Pharma (NASDAQ: LIFE) announced that it has selected an Investigational New Drug (IND) Candidate based on an immuno-modulatory and fibro-modulating Physiocrine domain fused to an Fc region of a human antibody, iMod.Fc. The selected iMod.Fc molecule is intended to address patients with severe pulmonary diseases with an immune and fibrotic component.
"The molecule developed in our iMod.Fc discovery program represents a major breakthrough as the first engineered Physiocrine with advantageous pharmaceutical properties... More
